Clinical Trial Update: Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating monthly alternating cycles of nal-IRI plus 5-FU/leucovorin (NALIRIFOX) and gemcitabine plus nab-paclitaxel (GnP) as first-line therapy …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Abraxane (paclitaxel albumin-bound)
• Gemcitabine (Gemcitabine)
• Leucovorin (folinic acid)
• Onivyde (irinotecan hydrochloride liposome injection)

Snippet

Sponsor: Northwell Health | Conditions: Pancreatic Ductal Adenocarcinoma | Phase 2 | Status: RECRUITING